RCOR News and Press, Renovacor Inc Com From 11/15/21

Renovacor (NYSE:RCOR): Q3 GAAP EPS of -$0.83. Press Release Cash position as of September 30, 2021, totaled $85.3M which, based on current projections, Renovacor believes will be sufficient to fund its operating expenses and capital expenditures requirements into 2023. For further details s...

Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing Released topline preclinical data demonstrating feasibility of REN-001 to...

Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies Renovacor, Inc. (NYSE: RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene ...

Renovacor, Inc. (NYSE: RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced that Magdalene Cook, M.D., Chief Executive ...

Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based...